C3 Inhibition With APL-2 Targets The Underlying Disease Process Of C3G Complement Hyperactivity And Improves Proteinuria - Apellis Medical Hub

C3 Inhibition With APL-2 Targets The Underlying Disease Process Of C3G Complement Hyperactivity And Improves Proteinuria

Share Via Email

Back to Conference Resources

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) and C3 Glomerulopathy (C3G) American Society of Nephrology (ASN) 2019

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.